What Protein Does Lipitor Primarily Regulate?
Lipitor (atorvastatin) primarily regulates HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway that produces cholesterol in the liver. By competitively inhibiting this protein, Lipitor reduces cholesterol synthesis, prompting the liver to clear more low-density lipoprotein (LDL) cholesterol from the blood.[1]
How Does HMG-CoA Reductase Inhibition Lower Cholesterol?
HMG-CoA reductase converts HMG-CoA to mevalonates, the first committed step in cholesterol biosynthesis. Lipitor binds to the enzyme's active site, mimicking its natural substrate and blocking the reaction. This drops intracellular cholesterol levels, upregulating LDL receptors on liver cells to pull LDL from circulation, typically cutting LDL by 40-60%.[1][2]
What Happens Without HMG-CoA Reductase Regulation?
Uninhibited HMG-CoA reductase drives excess cholesterol production, elevating LDL and atherosclerosis risk. Statins like Lipitor target this specifically; without it, plaque buildup accelerates cardiovascular events like heart attacks.[2]
Does Lipitor Affect Other Proteins?
Lipitor's main action is on HMG-CoA reductase, but downstream effects reduce isoprenoids, indirectly impacting proteins like small GTPases (Ras, Rho) involved in cell signaling and inflammation. These pleiotropic effects contribute to plaque stabilization, though cholesterol reduction remains primary.[1][3]
How Does This Compare to Other Statins?
All statins (e.g., simvastatin, rosuvastatin) inhibit HMG-CoA reductase, but Lipitor has high potency and lipophilicity for better tissue penetration. Rosuvastatin is more hydrophilic and liver-selective.[2]
Sources
[1]: DrugPatentWatch.com - Atorvastatin
[2]: FDA Label - Lipitor
[3]: PubMed - Statin Mechanisms